Patients who used copper intrauterine devices (Cu IUD) were found to have a lower risk of high-grade cervical neoplasms (cervical cancer) compared to users of the levonorgestrel-releasing intrauterine ...

Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...

This special structure creates a unique ultrasonographic appearance as described by Zalel and colleagues. [3] The typical sonographic appearance of the LNG device includes (Figures 1 and 2): Detection ...

Data showing that Liletta (Allergan/Medicines360), a 52-mg levonorgestrel-releasing intrauterine device (IUD), was highly effective in preventing pregnancy out to 5 years in slim to obese American ...

Turok, MD, MPH and Mitchell Creinin, MD Honored at the Society for Family Planning Annual Meeting In Pittsburgh ROSWELL, Ga., Oct. 27, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela ...

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...

Q: I’d love to have a reliable form of contraception that requires very little involvement on my part. I’ve been considering an IUD but I’ve heard horror stories about IUDs and pelvic infections. Are ...

Data from a large, 1-year postmarketing safety study conducted in Europe found that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation. The Food and ...

To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields—such as ...

Lower-dose IUDs were associated with an increased risk for ectopic pregnancy compared with higher-dose systems, according to a retrospective cohort study published in Obstetrics & Gynecology. Overall, ...

Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced that the journal Contraception has awarded the publication of Phase 3 data of MIUDELLA® (copper intrauterine system) one ...